Drugmaker CEOs doubt AI's promise to cure disease as Sanofi halts a Nurix-partnered program
According to The Wall Street Journal, drugmaker CEOs are not buying Silicon Valley's AI promises, and some biotech startups are deliberately skipping AI in discovery. Nurix said Sanofi has discontinued development of a STAT6 degrader identified jointly using the DEL-AI platform.
Who is affected and how
- pharmaceuticals
- AI-derived candidates must show clinical evidence; promises do not automatically turn into pipeline value.
Sources
- Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.wsj · Nov 4, 2026
- Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It. - WSJwsj.com · Nov 4, 2026
- Silicon Valley promises AI will cure disease. Drugmaker CEOs aren’t buying It. | Mintlivemint.com · Nov 4, 2026
- The biotech startups skipping AI for drug discoverystat · Nov 4, 2026
- AI Prognosis: The biotech startups skipping AI for drug discovery | STATstatnews.com · Nov 4, 2026
- Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 | Nurix Therapeutics, Inc.ir.nurixtx.com · Nov 3, 2026
- Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinicfiercebiotech.com · Nov 4, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.